Cohort of Ischemic STROKE Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-13

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has proven its superiority in this pathology.

Cohorts of patients with stroke are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool.

The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after ischemic stroke.

Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas:

* Descriptive epidemiology of ischemic stroke and cerebral reperfusion,
* Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs
* Assessment of the long-term effect of the treatment on the occurrence of disability, stroke recurrence and death,
* Quality of life and personal, familial, professional and social consequences of stroke,
* Research of new diagnostic and prognostic biomarkers,
* Research projects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke - HIBISCUS-STROKE II

NCT05263804

Ischemic Stroke

RECRUITING NA

Intravoxel Incoherent Motion Prognostic Value in the Initial Evaluation of Patients With Acute Ischemic Strokes Using 3 Tesla Magnetic Resonance Imaging

NCT03265860

Stroke Magnetic Resonance Imaging

COMPLETED

Carotid Plaque Characterization Using Innovative Ultrasound Techniques

NCT06804707

Carotid Atheroma

NOT_YET_RECRUITING NA

Endovascular Treatment in Ischemic Stroke Follow-up Evaluation

NCT03776877

Stroke, Acute

UNKNOWN

Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

NCT03268668

Stroke, Acute Biological Specimen Banks Biomarkers +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\> 18 years
* Ischemic Stroke confirmed by MRI
* Proximal arterial occlusion (ICA or M1)
* Eligible for thrombolysis and/or thrombectomy

Exclusion Criteria

* Patients residing\> 50 km from the Pierre Wertheimer Hospital (Lyon, France)
* Inability to perform the first sample (H0)
* Patient with progressive or uncontrolled cancer.
* Refusal to participate in the study or to sign the consent
* Lack of medical social coverage
* Deprivation of civil rights

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No